{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T19:47:34Z","timestamp":1788119254581,"version":"build-2803163510"},"reference-count":71,"publisher":"e-Century Publishing Corporation","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Cancer Res"],"DOI":"10.62347\/ttny4279","type":"journal-article","created":{"date-parts":[[2024,7,28]],"date-time":"2024-07-28T22:25:33Z","timestamp":1722205533000},"page":"3348-3371","source":"Crossref","is-referenced-by-count":13,"title":["Glypican-3 deficiency in liver cancer upregulates MAPK\/ERK pathway but decreases cell proliferation"],"prefix":"10.62347","volume":"14","author":[{"given":"Joon-Yong","family":"Chung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"48694","published-online":{"date-parts":[[2024]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71: 209-249.","journal-title":"CA Cancer J Clin"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"McGlynn KA, Petrick JL and El-Serag HB. Epidemiology of hepatocellular carcinoma. Hepatology 2021; 73 Suppl 1: 4-13.","DOI":"10.1002\/hep.31288"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS and Jemal A. Cancer statistics, 2023. CA Cancer J Clin 2023; 73: 17-48.","journal-title":"CA Cancer J Clin"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1146\/annurev.biochem.68.1.729","article-title":"Functions of cell surface heparan sulfate proteoglycans","volume":"68","author":"Bernfield","year":"1999","unstructured":"Bernfield M, Gotte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J and Zako M. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 1999; 68: 729-777.","journal-title":"Annu Rev Biochem"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/gb-2008-9-5-224","article-title":"Glypicans","volume":"9","author":"Filmus","year":"2008","unstructured":"Filmus J, Capurro M and Rast J. Glypicans. Genome Biol 2008; 9: 224.","journal-title":"Genome Biol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.tibs.2014.03.001","article-title":"Heparan sulfate signaling in cancer","volume":"39","author":"EH","year":"2014","unstructured":"Knelson EH, Nee JC and Blobe GC. Heparan sulfate signaling in cancer. Trends Biochem Sci 2014; 39: 277-288.","journal-title":"Trends Biochem Sci"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"483","DOI":"10.3389\/fendo.2018.00483","article-title":"Heparan sulfate and heparan sulfate proteoglycans in cancer initiation and progression","volume":"9","author":"Nagarajan","year":"2018","unstructured":"Nagarajan A, Malvi P and Wajapeyee N. Heparan sulfate and heparan sulfate proteoglycans in cancer initiation and progression. Front Endocrinol (Lausanne) 2018; 9: 483.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"708","DOI":"10.3389\/fonc.2019.00708","article-title":"The role of glypican-3 in regulating Wnt, YAP, and Hedgehog in liver cancer","volume":"9","author":"Kolluri","year":"2019","unstructured":"Kolluri A and Ho M. The role of glypican-3 in regulating Wnt, YAP, and Hedgehog in liver cancer. Front Oncol 2019; 9: 708.","journal-title":"Front Oncol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.ejca.2010.10.024","article-title":"Glypican-3: a new target for cancer immunotherapy","volume":"47","author":"Ho","year":"2011","unstructured":"Ho M and Kim H. Glypican-3: a new target for cancer immunotherapy. Eur J Cancer 2011; 47: 333-338.","journal-title":"Eur J Cancer"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Sha YL, Liu S, Yan WW and Dong B. Wnt\/beta-catenin signaling as a useful therapeutic target in hepatoblastoma. Biosci Rep 2019; 39: BSR20192466.","DOI":"10.1042\/BSR20192466"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3727\/105221616X693639","article-title":"Novel advances in understanding of molecular pathogenesis of hepatoblastoma: a Wnt\/beta-catenin perspective","volume":"17","author":"Bell","year":"2017","unstructured":"Bell D, Ranganathan S, Tao J and Monga SP. Novel advances in understanding of molecular pathogenesis of hepatoblastoma: a Wnt\/beta-catenin perspective. Gene Expr 2017; 17: 141-154.","journal-title":"Gene Expr"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"16018","DOI":"10.1038\/nrdp.2016.18","article-title":"Hepatocellular carcinoma","volume":"2","author":"Llovet","year":"2016","unstructured":"Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M and Gores G. Hepatocellular carcinoma. Nat Rev Dis Primers 2016; 2: 16018.","journal-title":"Nat Rev Dis Primers"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1038\/modpathol.3800436","article-title":"The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma","volume":"18","author":"Yamauchi","year":"2005","unstructured":"Yamauchi N, Watanabe A, Hishinuma M, Ohashi K, Midorikawa Y, Morishita Y, Niki T, Shibahara J, Mori M, Makuuchi M, Hippo Y, Kodama T, Iwanari H, Aburatani H and Fukayama M. The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol 2005; 18: 1591-1598.","journal-title":"Mod Pathol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.humpath.2007.06.006","article-title":"Expression of glypican 3 in hepatoblastoma: an immunohistochemical study of 65 cases","volume":"39","author":"Zynger","year":"2008","unstructured":"Zynger DL, Gupta A, Luan C, Chou PM, Yang GY and Yang XJ. Expression of glypican 3 in hepatoblastoma: an immunohistochemical study of 65 cases. Hum Pathol 2008; 39: 224-230.","journal-title":"Hum Pathol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S0016-5085(03)00689-9","article-title":"Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma","volume":"125","author":"Capurro","year":"2003","unstructured":"Capurro M, Wanless IR, Sherman M, Deboer G, Shi W, Miyoshi E and Filmus J. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003; 125: 89-97.","journal-title":"Gastroenterology"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1158\/0008-5472.CAN-03-2191","article-title":"Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma","volume":"64","author":"Hippo","year":"2004","unstructured":"Hippo Y, Watanabe K, Watanabe A, Midorikawa Y, Yamamoto S, Ihara S, Tokita S, Iwanari H, Ito Y, Nakano K, Nezu J, Tsunoda H, Yoshino T, Ohizumi I, Tsuchiya M, Ohnishi S, Makuuchi M, Hamakubo T, Kodama T and Aburatani H. Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma. Cancer Res 2004; 64: 2418-2423.","journal-title":"Cancer Res"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"5780","DOI":"10.3390\/ijms22115780","article-title":"Application of immunohistochemistry in the pathological diagnosis of liver tumors","volume":"22","author":"Takahashi","year":"2021","unstructured":"Takahashi Y, Dungubat E, Kusano H, Ganbat D, Tomita Y, Odgerel S and Fukusato T. Application of immunohistochemistry in the pathological diagnosis of liver tumors. Int J Mol Sci 2021; 22: 5780.","journal-title":"Int J Mol Sci"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1111\/j.1349-7006.2009.01206.x","article-title":"Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma","volume":"100","author":"Shirakawa","year":"2009","unstructured":"Shirakawa H, Suzuki H, Shimomura M, Kojima M, Gotohda N, Takahashi S, Nakagohri T, Konishi M, Kobayashi N, Kinoshita T and Nakatsura T. Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma. Cancer Sci 2009; 100: 1403-1407.","journal-title":"Cancer Sci"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.trecan.2018.09.004","article-title":"Glypicans as cancer therapeutic targets","volume":"4","author":"Li","year":"2018","unstructured":"Li N, Gao W, Zhang YF and Ho M. Glypicans as cancer therapeutic targets. Trends Cancer 2018; 4: 741-754.","journal-title":"Trends Cancer"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/path.6063","article-title":"Oncofetal protein glypican-3 is a biomarker and critical regulator of function for neuroendocrine cells in prostate cancer","volume":"260","author":"Butler","year":"2023","unstructured":"Butler W, Xu L, Zhou Y, Cheng Q, Hauck JS, He Y, Marek R, Hartman Z, Cheng L, Yang Q, Wang ME, Chen M, Zhang H, Armstrong AJ and Huang J. Oncofetal protein glypican-3 is a biomarker and critical regulator of function for neuroendocrine cells in prostate cancer. J Pathol 2023; 260: 43-55.","journal-title":"J Pathol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1016\/j.ajpath.2018.05.014","article-title":"Glypican 3 overexpression across a broad spectrum of tumor types discovered with functional genomic mRNA profiling of a large cancer database","volume":"188","author":"Moek","year":"2018","unstructured":"Moek KL, Fehrmann RSN, van der Vegt B, de Vries EGE and de Groot DJA. Glypican 3 overexpression across a broad spectrum of tumor types discovered with functional genomic mRNA profiling of a large cancer database. Am J Pathol 2018; 188: 1973-1981.","journal-title":"Am J Pathol"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Ishiguro T, Sano Y, Komatsu SI, Kamata-Sakurai M, Kaneko A, Kinoshita Y, Shiraiwa H, Azuma Y, Tsunenari T, Kayukawa Y, Sonobe Y, Ono N, Sakata K, Fujii T, Miyazaki Y, Noguchi M, Endo M, Harada A, Frings W, Fujii E, Nanba E, Narita A, Sakamoto A, Wakabayashi T, Konishi H, Segawa H, Igawa T, Tsushima T, Mutoh H, Nishito Y, Takahashi M, Stewart L, ElGabry E, Kawabe Y, Ishigai M, Chiba S, Aoki M, Hattori K and Nezu J. An anti-glypican 3\/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors. Sci Transl Med 2017; 9: eaal4291.","DOI":"10.1126\/scitranslmed.aal4291"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1111\/febs.12126","article-title":"Glypican-3: a marker and a therapeutic target in hepatocellular carcinoma","volume":"280","author":"Filmus","year":"2013","unstructured":"Filmus J and Capurro M. Glypican-3: a marker and a therapeutic target in hepatocellular carcinoma. FEBS J 2013; 280: 2471-2476.","journal-title":"FEBS J"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.febslet.2013.10.002","article-title":"Glypican-3 antibodies: a new therapeutic target for liver cancer","volume":"588","author":"Feng","year":"2014","unstructured":"Feng M and Ho M. Glypican-3 antibodies: a new therapeutic target for liver cancer. FEBS Lett 2014; 588: 377-382.","journal-title":"FEBS Lett"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","article-title":"177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial","volume":"22","author":"JR","year":"2021","unstructured":"Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, Mittra E, Wolin EM, Yao JC, Pavel ME, Grande E, Van Cutsem E, Seregni E, Duarte H, Gericke G, Bartalotta A, Mariani MF, Demange A, Mutevelic S and Krenning EP; NETTER-1 investigators. 177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol 2021; 22: 1752-1763.","journal-title":"Lancet Oncol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, Tagawa ST, Nordquist LT, Vaishampayan N, El-Haddad G, Park CH, Beer TM, Armour A, Perez-Contreras WJ, DeSilvio M, Kpamegan E, Gericke G, Messmann RA, Morris MJ and Krause BJ; VISION Investigators. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med 2021; 385: 1091-1103.","journal-title":"N Engl J Med"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"799","DOI":"10.2967\/jnumed.113.132118","article-title":"Glypican-3-targeted 89Zr PET imaging of hepatocellular carcinoma","volume":"55","author":"Sham","year":"2014","unstructured":"Sham JG, Kievit FM, Grierson JR, Miyaoka RS, Yeh MM, Zhang M, Yeung RS, Minoshima S and Park JO. Glypican-3-targeted 89Zr PET imaging of hepatocellular carcinoma. J Nucl Med 2014; 55: 799-804.","journal-title":"J Nucl Med"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1007\/s00259-022-05723-x","article-title":"GPC3-targeted immunoPET imaging of hepatocellular carcinomas","volume":"49","author":"An","year":"2022","unstructured":"An S, Zhang D, Zhang Y, Wang C, Shi L, Wei W, Huang G and Liu J. GPC3-targeted immunoPET imaging of hepatocellular carcinomas. Eur J Nucl Med Mol Imaging 2022; 49: 2682-2692.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"3731","DOI":"10.1038\/s41598-021-82172-w","article-title":"Glypican-3 targeted delivery of 89Zr and 90Y as a theranostic radionuclide platform for hepatocellular carcinoma","volume":"11","author":"Labadie","year":"2021","unstructured":"Labadie KP, Ludwig AD, Lehnert AL, Hamlin DK, Kenoyer AL, Sullivan KM, Daniel SK, Mihailovic TN, Sham JG, Orozco JJ, Yeung RS, Chen DL, Wilbur DS, Miyaoka RS and Park JO. Glypican-3 targeted delivery of 89Zr and 90Y as a theranostic radionuclide platform for hepatocellular carcinoma. Sci Rep 2021; 11: 3731.","journal-title":"Sci Rep"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13550-018-0374-8","article-title":"I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma","volume":"8","author":"JA","year":"2018","unstructured":"Carrasquillo JA, O’Donoghue JA, Beylergil V, Ruan S, Pandit-Taskar N, Larson SM, Smith-Jones PM, Lyashchenko SK, Ohishi N, Ohtomo T and Abou-Alfa GK. I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma. EJNMMI Res 2018; 8: 20.","journal-title":"EJNMMI Res"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.2967\/jnumed.122.265171","article-title":"Site-specifically conjugated single-domain antibody successfully identifies glypican-3-expressing liver cancer by immuno-PET","volume":"64","author":"Fayn","year":"2023","unstructured":"Fayn S, King AP, Gutsche NT, Duan Z, Buffington J, Olkowski CP, Fu Y, Hong J, Sail D, Baidoo KE, Swenson RE, Cheloha RW, Ho M, Choyke PL and Escorcia FE. Site-specifically conjugated single-domain antibody successfully identifies glypican-3-expressing liver cancer by immuno-PET. J Nucl Med 2023; 64: 1017-1023.","journal-title":"J Nucl Med"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3390\/molecules26010004","article-title":"Glypican-3-targeted alpha particle therapy for hepatocellular carcinoma","volume":"26","author":"Bell","year":"2020","unstructured":"Bell MM, Gutsche NT, King AP, Baidoo KE, Kelada OJ, Choyke PL and Escorcia FE. Glypican-3-targeted alpha particle therapy for hepatocellular carcinoma. Molecules 2020; 26: 4.","journal-title":"Molecules"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.2967\/jnumed.121.262562","article-title":"Glypican-3-targeted 227Th alpha-therapy reduces tumor burden in an orthotopic xenograft murine model of hepatocellular carcinoma","volume":"63","author":"Labadie","year":"2022","unstructured":"Labadie KP, Hamlin DK, Kenoyer A, Daniel SK, Utria AF, Ludwig AD, Kenerson HL, Li L, Sham JG, Chen DL, Orozco JJ, Yeung RS, Orvig C, Li Y, Wilbur DS and Park JO. Glypican-3-targeted 227Th alpha-therapy reduces tumor burden in an orthotopic xenograft murine model of hepatocellular carcinoma. J Nucl Med 2022; 63: 1033-1038.","journal-title":"J Nucl Med"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.7150\/jca.39972","article-title":"Glypican-3: a new target for diagnosis and treatment of hepatocellular carcinoma","volume":"11","author":"Guo","year":"2020","unstructured":"Guo M, Zhang H, Zheng J and Liu Y. Glypican-3: a new target for diagnosis and treatment of hepatocellular carcinoma. J Cancer 2020; 11: 2008-2021.","journal-title":"J Cancer"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Berman RM, Kelada OJ, Gutsche NT, Natarajan R, Swenson RE, Fu Y, Hong J, Ho M, Choyke PL and Escorcia FE. In vitro performance of published glypican 3-targeting peptides TJ12P1 and L5 indicates lack of specificity and potency. Cancer Biother Radiopharm 2019; 34: 498-503.","DOI":"10.1089\/cbr.2019.2888"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/nprot.2017.016","article-title":"Genome-scale CRISPRCas9 knockout and transcriptional activation screening","volume":"12","author":"Joung","year":"2017","unstructured":"Joung J, Konermann S, Gootenberg JS, Abudayyeh OO, Platt RJ, Brigham MD, Sanjana NE and Zhang F. Genome-scale CRISPRCas9 knockout and transcriptional activation screening. Nat Protoc 2017; 12: 828-863.","journal-title":"Nat Protoc"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Kelada OJ, Gutsche NT, Bell M, Berman RM, Baidoo KE, Warner BM, Szajek LP, Hong J, Ho M, Choyke P and Escorcia FE. ImmunoPET as stoichiometric sensor for glypican-3 in models of hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2020; 108: S180-181.","DOI":"10.1016\/j.ijrobp.2020.07.966"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"3499655","DOI":"10.1155\/2023\/3499655","article-title":"Immuno-PET imaging of siglec-15 using the zirconium-89-labeled therapeutic antibody, NC318","volume":"2023","author":"Jagoda","year":"2023","unstructured":"Jagoda EM, Basuli F, Olkowski C, Weiss I, Phelps TE, Wong KR, Ton AT, Lane KC, Adler S, Butcher D, Edmondson EF, Langermann S and Choyke PL. Immuno-PET imaging of siglec-15 using the zirconium-89-labeled therapeutic antibody, NC318. Mol Imaging 2023; 2023: 3499655.","journal-title":"Mol Imaging"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1097\/CAD.0b013e32833f5d68","article-title":"Generation of a humanized anti-glypican 3 antibody by CDR grafting and stability optimization","volume":"21","author":"Nakano","year":"2010","unstructured":"Nakano K, Ishiguro T, Konishi H, Tanaka M, Sugimoto M, Sugo I, Igawa T, Tsunoda H, Kinoshita Y, Habu K, Orita T, Tsuchiya M, Hattori K and Yamada-Okabe H. Generation of a humanized anti-glypican 3 antibody by CDR grafting and stability optimization. Anticancer Drugs 2010; 21: 907-916.","journal-title":"Anticancer Drugs"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"969","DOI":"10.3892\/mmr.2013.1279","article-title":"Overexpression of GPC3 inhibits hepatocellular carcinoma cell proliferation and invasion through induction of apoptosis","volume":"7","author":"Pan","year":"2013","unstructured":"Pan Z, Chen C, Long H, Lei C, Tang G, Li L, Feng J and Chen F. Overexpression of GPC3 inhibits hepatocellular carcinoma cell proliferation and invasion through induction of apoptosis. Mol Med Rep 2013; 7: 969-974.","journal-title":"Mol Med Rep"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1002\/hep.24417","article-title":"Hepatocyte proliferation and hepatomegaly induced by phenobarbital and 1,4-bis [2-(3,5-dichloropyridyloxy)] benzene is suppressed in hepatocyte-targeted glypican 3 transgenic mice","volume":"54","author":"Lin","year":"2011","unstructured":"Lin CW, Mars WM, Paranjpe S, Donthamsetty S, Bhave VS, Kang LI, Orr A, Bowen WC, Bell AW and Michalopoulos GK. Hepatocyte proliferation and hepatomegaly induced by phenobarbital and 1,4-bis [2-(3,5-dichloropyridyloxy)] benzene is suppressed in hepatocyte-targeted glypican 3 transgenic mice. Hepatology 2011; 54: 620-630.","journal-title":"Hepatology"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.3892\/ijo.2015.2827","article-title":"Glypican-3 promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells through ERK signaling pathway","volume":"46","author":"Wu","year":"2015","unstructured":"Wu Y, Liu H, Weng H, Zhang X, Li P, Fan CL, Li B, Dong PL, Li L, Dooley S and Ding HG. Glypican-3 promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells through ERK signaling pathway. Int J Oncol 2015; 46: 1275-1285.","journal-title":"Int J Oncol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1593\/neo.11664","article-title":"Suppression of glypican 3 inhibits growth of hepatocellular carcinoma cells through up-regulation of TGF-beta2","volume":"13","author":"Sun","year":"2011","unstructured":"Sun CK, Chua MS, He J and So SK. Suppression of glypican 3 inhibits growth of hepatocellular carcinoma cells through up-regulation of TGF-beta2. Neoplasia 2011; 13: 735-747.","journal-title":"Neoplasia"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1002\/jcb.24404","article-title":"Knockdown of GPC3 inhibits the proliferation of Huh7 hepatocellular carcinoma cells through down-regulation of YAP","volume":"114","author":"Miao","year":"2013","unstructured":"Miao HL, Pan ZJ, Lei CJ, Wen JY, Li MY, Liu ZK, Qiu ZD, Lin MZ, Chen NP and Chen M. Knockdown of GPC3 inhibits the proliferation of Huh7 hepatocellular carcinoma cells through down-regulation of YAP. J Cell Biochem 2013; 114: 625-631.","journal-title":"J Cell Biochem"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.jss.2022.09.011","article-title":"Inhibition of glypican-3 cleavage results in reduced cell proliferation in a liver cancer cell line","volume":"282","author":"Schepers","year":"2023","unstructured":"Schepers EJ, Lake C, Glaser K and Bondoc AJ. Inhibition of glypican-3 cleavage results in reduced cell proliferation in a liver cancer cell line. J Surg Res 2023; 282: 118-128.","journal-title":"J Surg Res"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1093\/carcin\/bgn091","article-title":"Glypican-3-mediated oncogenesis involves the Insulin-like growth factor-signaling pathway","volume":"29","author":"Cheng","year":"2008","unstructured":"Cheng W, Tseng CJ, Lin TT, Cheng I, Pan HW, Hsu HC and Lee YM. Glypican-3-mediated oncogenesis involves the Insulin-like growth factor-signaling pathway. Carcinogenesis 2008; 29: 1319-1326.","journal-title":"Carcinogenesis"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1083\/jcb.200302152","article-title":"Processing by proprotein convertases is required for glypican-3 modulation of cell survival, Wnt signaling, and gastrulation movements","volume":"163","author":"De Cat","year":"2003","unstructured":"De Cat B, Muyldermans SY, Coomans C, Degeest G, Vanderschueren B, Creemers J, Biemar F, Peers B and David G. Processing by proprotein convertases is required for glypican-3 modulation of cell survival, Wnt signaling, and gastrulation movements. J Cell Biol 2003; 163: 625-635.","journal-title":"J Cell Biol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"7574","DOI":"10.1074\/jbc.272.12.7574","article-title":"OCI-5\/rat glypican-3 binds to fibroblast growth factor-2 but not to insulin-like growth factor-2","volume":"272","author":"HH","year":"1997","unstructured":"Song HH, Shi W and Filmus J. OCI-5\/rat glypican-3 binds to fibroblast growth factor-2 but not to insulin-like growth factor-2. J Biol Chem 1997; 272: 7574-7577.","journal-title":"J Biol Chem"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1002\/hep.22202","article-title":"Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma","volume":"47","author":"Lai","year":"2008","unstructured":"Lai JP, Sandhu DS, Yu C, Han T, Moser CD, Jackson KK, Guerrero RB, Aderca I, Isomoto H, Garrity-Park MM, Zou H, Shire AM, Nagorney DM, Sanderson SO, Adjei AA, Lee JS, Thorgeirsson SS and Roberts LR. Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma. Hepatology 2008; 47: 1211-1222.","journal-title":"Hepatology"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"Gao W, Kim H and Ho M. Human monoclonal antibody targeting the heparan sulfate chains of glypican-3 inhibits HGF-mediated migration and motility of hepatocellular carcinoma cells. PLoS One 2015; 10: e0137664.","DOI":"10.1371\/journal.pone.0137664"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/ijc.10856","article-title":"Glypican-3, overexpressed in hepatocellular carcinoma, modulates FGF2 and BMP-7 signaling","volume":"103","author":"Midorikawa","year":"2003","unstructured":"Midorikawa Y, Ishikawa S, Iwanari H, Imamura T, Sakamoto H, Miyazono K, Kodama T, Makuuchi M and Aburatani H. Glypican-3, overexpressed in hepatocellular carcinoma, modulates FGF2 and BMP-7 signaling. Int J Cancer 2003; 103: 455-465.","journal-title":"Int J Cancer"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"3521","DOI":"10.3748\/wjg.v16.i28.3521","article-title":"Association of glypican-3 expression with growth signaling molecules in hepatocellular carcinoma","volume":"16","author":"Akutsu","year":"2010","unstructured":"Akutsu N, Yamamoto H, Sasaki S, Taniguchi H, Arimura Y, Imai K and Shinomura Y. Association of glypican-3 expression with growth signaling molecules in hepatocellular carcinoma. World J Gastroenterol 2010; 16: 3521-3528.","journal-title":"World J Gastroenterol"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/S1016-8478(23)12884-6","article-title":"Cellular changes resulting from forced expression of glypican-3 in hepatocellular carcinoma cells","volume":"21","author":"MH","year":"2006","unstructured":"Kwack MH, Choi BY and Sung YK. Cellular changes resulting from forced expression of glypican-3 in hepatocellular carcinoma cells. Mol Cells 2006; 21: 224-228.","journal-title":"Mol Cells"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1101\/gad.1662308","article-title":"Akt-dependent regulation of NF-{kappa}B is controlled by mTOR and Raptor in association with IKK","volume":"22","author":"Dan","year":"2008","unstructured":"Dan HC, Cooper MJ, Cogswell PC, Duncan JA, Ting JP and Baldwin AS. Akt-dependent regulation of NF-{kappa}B is controlled by mTOR and Raptor in association with IKK. Genes Dev 2008; 22: 1490-1500.","journal-title":"Genes Dev"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"6245","DOI":"10.1158\/0008-5472.CAN-04-4244","article-title":"Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling","volume":"65","author":"Capurro","year":"2005","unstructured":"Capurro MI, Xiang YY, Lobe C and Filmus J. Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res 2005; 65: 6245-6254.","journal-title":"Cancer Res"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1242\/jcs.140871","article-title":"Glypican-3 binds to Frizzled and plays a direct role in the stimulation of canonical Wnt signaling","volume":"127","author":"Capurro","year":"2014","unstructured":"Capurro M, Martin T, Shi W and Filmus J. Glypican-3 binds to Frizzled and plays a direct role in the stimulation of canonical Wnt signaling. J Cell Sci 2014; 127: 1565-1575.","journal-title":"J Cell Sci"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1002\/hep.30646","article-title":"A frizzled-like cysteine-rich domain in glypican-3 mediates wnt binding and regulates hepatocellular carcinoma tumor growth in mice","volume":"70","author":"Li","year":"2019","unstructured":"Li N, Wei L, Liu X, Bai H, Ye Y, Li D, Li N, Baxa U, Wang Q, Lv L, Chen Y, Feng M, Lee B, Gao W and Ho M. A frizzled-like cysteine-rich domain in glypican-3 mediates wnt binding and regulates hepatocellular carcinoma tumor growth in mice. Hepatology 2019; 70: 1231-1245.","journal-title":"Hepatology"},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"Buechel D, Sugiyama N, Rubinstein N, Saxena M, Kalathur RKR, Luond F, Vafaizadeh V, Valenta T, Hausmann G, Cantu C, Basler K and Christofori G. Parsing beta-catenin’s cell adhesion and Wnt signaling functions in malignant mammary tumor progression. Proc Natl Acad Sci U S A 2021; 118: e2020227118.","DOI":"10.1073\/pnas.2020227118"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1002\/hep.26996","article-title":"Inactivation of Wnt signaling by a human antibody that recognizes the heparan sulfate chains of glypican-3 for liver cancer therapy","volume":"60","author":"Gao","year":"2014","unstructured":"Gao W, Kim H, Feng M, Phung Y, Xavier CP, Rubin JS and Ho M. Inactivation of Wnt signaling by a human antibody that recognizes the heparan sulfate chains of glypican-3 for liver cancer therapy. Hepatology 2014; 60: 576-587.","journal-title":"Hepatology"},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"Sun L, Gao F, Gao Z, Ao L, Li N, Ma S, Jia M, Li N, Lu P, Sun B, Ho M, Jia S, Ding T and Gao W. Shed antigen-induced blocking effect on CAR-T cells targeting glypican-3 in hepatocellular carcinoma. J Immunother Cancer 2021; 9: e001875.","DOI":"10.1136\/jitc-2020-001875"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"45932","DOI":"10.1038\/srep45932","article-title":"Glypican 3 as a serum marker for hepatoblastoma","volume":"7","author":"Zhou","year":"2017","unstructured":"Zhou S, O’Gorman MR, Yang F, Andresen K and Wang L. Glypican 3 as a serum marker for hepatoblastoma. Sci Rep 2017; 7: 45932.","journal-title":"Sci Rep"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/j.1440-1746.2009.05988.x","article-title":"Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers","volume":"25","author":"Tangkijvanich","year":"2010","unstructured":"Tangkijvanich P, Chanmee T, Komtong S, Mahachai V, Wisedopas N, Pothacharoen P and Kongtawelert P. Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers. J Gastroenterol Hepatol 2010; 25: 129-137.","journal-title":"J Gastroenterol Hepatol"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"9608","DOI":"10.1038\/s41598-017-10083-w","article-title":"Development of an Affimer-antibody combined immunological diagnosis kit for glypican-3","volume":"7","author":"Xie","year":"2017","unstructured":"Xie C, Tiede C, Zhang X, Wang C, Li Z, Xu X, McPherson MJ, Tomlinson DC and Xu W. Development of an Affimer-antibody combined immunological diagnosis kit for glypican-3. Sci Rep 2017; 7: 9608.","journal-title":"Sci Rep"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1097\/PPO.0000000000000435","article-title":"Radiomics, radiogenomics, and next-generation molecular imaging to augment diagnosis of hepatocellular carcinoma","volume":"26","author":"Bell","year":"2020","unstructured":"Bell M, Turkbey EB and Escorcia FE. Radiomics, radiogenomics, and next-generation molecular imaging to augment diagnosis of hepatocellular carcinoma. Cancer J 2020; 26: 108-115.","journal-title":"Cancer J"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1021\/acsmedchemlett.3c00213","article-title":"Development of Iodinated indocyanine green analogs as a strategy for targeted therapy of liver cancer","volume":"14","author":"Marker","year":"2023","unstructured":"Marker SC, Espinoza AF, King AP, Woodfield SE, Patel RH, Baidoo K, Nix MN, Ciaramicoli LM, Chang YT, Escorcia FE, Vasudevan SA and Schnermann MJ. Development of Iodinated indocyanine green analogs as a strategy for targeted therapy of liver cancer. ACS Med Chem Lett 2023; 14: 1208-1215.","journal-title":"ACS Med Chem Lett"},{"key":"ref65","doi-asserted-by":"publisher","unstructured":"Mena E, Shih J, Chung JY, Jones J, Rabiee A, Monge C, Turkbey B, Lindenberg L, Salerno KE, Kassin M, Wood B, Hernandez J, Maass-Moreno R, Saboury B, Jakhete N, Molitoris JK, Unger KR, Choyke PL and Escorcia FE. Functional Imaging of Liver Cancer (FLIC): study protocol of a phase 2 trial of 18F-DCFPyL PET\/CT imaging for patients with hepatocellular carcinoma. PLoS One 2022; 17: e0277407.","DOI":"10.1371\/journal.pone.0277407"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"4654","DOI":"10.1111\/cas.15965","article-title":"Near-infrared photoimmunotherapy in the models of hepatocellular carcinomas using cetuximab-IR700","volume":"114","author":"Takao","year":"2023","unstructured":"Takao S, Fukushima H, King AP, Kato T, Furusawa A, Okuyama S, Kano M, Choyke PL, Escorcia FE and Kobayashi H. Near-infrared photoimmunotherapy in the models of hepatocellular carcinomas using cetuximab-IR700. Cancer Sci 2023; 114: 4654-4663.","journal-title":"Cancer Sci"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s00726-017-2517-z","article-title":"Imaging the expression of glypican-3 in hepatocellular carcinoma by PET","volume":"50","author":"Wang","year":"2018","unstructured":"Wang Z, Han YJ, Huang S, Wang M, Zhou WL, Li HS, Wang QS and Wu HB. Imaging the expression of glypican-3 in hepatocellular carcinoma by PET. Amino Acids 2018; 50: 309-320.","journal-title":"Amino Acids"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1007\/s11307-019-01356-z","article-title":"Radiofluorinated GPC3-binding peptides for PET imaging of hepatocellular carcinoma","volume":"22","author":"Li","year":"2020","unstructured":"Li Y, Zhang J, Gu J, Hu K, Huang S, Conti PS, Wu H and Chen K. Radiofluorinated GPC3-binding peptides for PET imaging of hepatocellular carcinoma. Mol Imaging Biol 2020; 22: 134-143.","journal-title":"Mol Imaging Biol"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"586","DOI":"10.2967\/jnumed.123.266766","article-title":"Peptide binder to glypican-3 as a theranostic agent for hepatocellular carcinoma","volume":"65","author":"Lin","year":"2024","unstructured":"Lin F, Clift R, Ehara T, Yanagida H, Horton S, Noncovich A, Guest M, Kim D, Salvador K, Richardson S, Miller T, Han G, Bhat A, Song K and Li G. Peptide binder to glypican-3 as a theranostic agent for hepatocellular carcinoma. J Nucl Med 2024; 65: 586-592.","journal-title":"J Nucl Med"},{"key":"ref70","doi-asserted-by":"publisher","unstructured":"Xie C, Monge B MC, Mabry-Hrones D, Coffman KL, Hicks S, Redd B, Wood B, Highfill S, Ho M and Greten TF. A phase I study of GPC3 targeted CAR-T cell therapy in advanced GPC3-expressing hepatocellular carcinoma (HCC). J Clin Oncol 2023; 41: Suppl TPS624.","DOI":"10.1200\/JCO.2023.41.4_suppl.TPS624"}],"container-title":["American Journal of Cancer Research"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajcr\/14\/7\/ajcr0157118.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:54:29Z","timestamp":1766022869000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajcr\/14\/7\/ajcr0157118.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":71,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.62347\/ttny4279","relation":{},"ISSN":["2156-6976"],"issn-type":[{"value":"2156-6976","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]}}}